Those with hemophilia face heightened risks of depression and anxiety due to pain and joint issues, impacting their overall mental health and quality of life.
Switching to rFVIIIFc significantly reduces bleeding rates and injection frequency for hemophilia A patients, enhancing treatment efficacy and quality of life.
The FDA's approval of Alhemo (concizumab-mtci) revolutionizes hemophilia treatment, offering a simpler, subcutaneous injection for better bleed control and patient independence.
BioMarin's Roctavian gene therapy shows long-term effectiveness in treating severe hemophilia A, reducing bleeding and improving quality of life for patients.
Switching to extended half-life from standard half-life therapies for hemophilia enhances treatment adherence and reduces infusion frequency, despite initial cost increases.